Urinary chiro-and myo-inositol levels as a biological marker for type 2 diabetes mellitus

Disease Markers

Volumn 33, Issue 4, 2012, Pages 193-199

  Hong, Jun Hwa ^a   Jang, Hye Won ^a   Kang, Yea Eun ^a   Lee, Ju Hee ^a   Kim, Koon Soon ^a   Kim, Hyun Jin ^a   Park, Kyu Ri ^b   Ku, Bon Jeong ^a  

^a Chungnam National University   (South Korea)

^b Korean Association of Health Promotion   (South Korea)

Author keywords

Chiro inositol; diabetes mellitus; myo inositol

Indexed keywords

BIOLOGICAL MARKER; CHIRO INOSITOL; INOSITOL; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MAJOR CLINICAL STUDY; MALE; MASS SPECTROMETRY; NON INSULIN DEPENDENT DIABETES MELLITUS; PREDICTIVE VALUE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; URINARY EXCRETION; URINE LEVEL;

EID: 84872242542     PISSN: 02780240     EISSN: 18758630     Source Type: Journal    
DOI: 10.3233/DMA-2012-0925     Document Type: Article

References (24)

1. S. Wild, G. Roglic, A. Green, R. Sicree and H. King, Global prevalence of diabetes: estimates for the year 2000 and projections for 2030, Diabetes care 27 (2004), 1047-1053.
2. The Fourth Korea National Health and Nutrition Examination Survey (KNHANES IV-3) data, Korea Centers for Disease Control and Prevention, 2010, from http://knhanes.cdc.go.kr/.
3. R.L. Hanson, R.E. Pratley, C. Bogardus, K.M. Narayan, J.M. Roumain, G. Imperatore, P.H. Benntt, and W.C. Knowler, Evaluation of simple indices of insulin sensitivity and insulin secretion for use in epidemiologic studies, Am J Epidemiol 151 (2000), 190-198.
4. M.P. Stern, M. Rosenthal, S.M. Haffner, H.P. Hazuda, and L.J. Franco, Sex difference in the effects of sociocultural status on diabetes and cardiovascular risk factors in Mexican Americans. the San Antonio Heart Study, Am J Epidemiol 120 (1984), 834-851.
5. M.A.Abdul-Ghani, K.William, R.A.DeFronzo, andM. Stern, What is the best predictor of future type 2 diabetes? Diabetes Care 30 (2007), 1544-1548.
6. M.P. Stern, K. Williams, and S.M. Haffner, Identification of persons at high risk for type 2 diabetes mellitus: Do we need the oral glucose tolerance test? Ann Intern Med 136 (2002), 575-581.
7. H.S. Kahn, Y.J. Cheng, T.J. Thompson, G. Imperatore, and E.W. Gregg, Two risk-scoring systems for predicting incident diabetes mellitus in U.S. adults age 45 to 64 years, Ann Intern Med 150 (2009), 741-751.
8. S.E. Kahn, The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of type 2 diabetes, Diabetologia 46 (2003), 3-19.
9. G. Romero and J. Larner, Insulinmediators and themechanism of insulin action, Adv Pharmacol 24 (1993), 21-50.
10. A.R. Saltiel, Second messengers of insulin action, Diabetes Care 13 (1990), 244-256.
11. R.E. Jr Ostlund, J.B. McGill, I. Herskowitz, D.M. Kipnis, J.V. Santiago, and W. Sherman, D-chiro-inositol metabolism in diabetes mellitus, Proc Natl Acad Sci USA 90 (1993), 9988-9992.
12. J.M. Kawa, R. Przybylski, and C.G. Talor, Urinary chiroinositol and myo-inositol excretion is elevated in diabetic db/db mouse and streptozotocin diabetic rat, Exp Biol Med 228 (2003), 907-914.
13. J.P. Baillargeon, E. Diamanti-Kandarakis, R.E. Jr Ostlund, T. Apridonidze, M.J. Iuorno, and J.E. Nestler, Altered D-chiroinositol urinary clearance in women with polycystic ovary syndrome, Diabetes Care 29 (2006), 300-305.
14. A.S. Kennington, C.R. Hill, J. Craig, C. Bogardus, I. Raz, H.K. Ortmeyer, B.C. Hansen, G. Romero, and J. Larner, Low urinary chiro-inositol excretion in non-insulin-dependent diabetes mellitus, N Engl J Med 323 (1990), 373-378.
15. I. Asplin, G. Galasko, and J. Larner, chiro-inositol defiency and insulin resistance: A comparison of the chiro-inositol-and myo-inositol-containing insulinmediators isolated from urine, hemodialysate, and muscle of control and type II diabetic subjects, Proc Natl Acad Sci USA 90 (1993), 5924-5928.
16. J.H. Kim, G.W. Kim, M.Y. Lee, J.Y. Shin, Y.G. Shin, S.B.Koh, and C.H. Chung, Role of HbA1c in the screening of diabetes mellitus in a Korean rural community, Diabetes Metab J 36 (2012), 37-42.
17. M.J.McNeely, E.J. Boyko, D.L. Leonetti, S.E.Kahn, andW.Y. Fujimoto, Comparison of a clinical model, the oral glucose tolerance test, and fasting glucose for prediction of type 2 diabetes risk in Japanese Americans, Diabetes Care 26 (2003), 758-763.
18. M.A. Abdul-Ghani and R.A. Defronzo, Plasma glucose concentration and prediction of future risk of type 2 diabetes, Diabetes Care 32 (2009), 194-198.
19. P. Beemster, P.Groenen, and R. Steegers-Theunissen, Involvement of inositol in reproduction, Nutr Rev 60 (2002), 80-87.
20. Y. Pak, L. Huang, K. Lilley, and J. Larner, In vivo conversion of [3H]myo-inositol to [3H]chiro-inositol in rat tissues, J Biol Chem 267 (1992), 16904-16910.
21. J. Larner, D-chiro-inositol-Its functional role in insulin action and its deficit in insulin resistance, Int J Exp Diabetes Res 3 (2002), 47-60.
22. S. Suzuki, H. Kawasaki, Y. Satoh, M. Ohtomo, M. Matsumoto, M. Hirai, A. Hirai, H. Hirai, S. Hirai, M. Onoda, M. Matsumoto, Y. Hinikio, H. Akai, J. Craig, J. Larner, and T. Toyota, Urinary chiro-inositol excretion is an index marker of insulin sensitivity in Japanese type II diabetes, Diabetes Care 17 (1994), 1465-1468.
23. W.H. Daughaday and J. Larner, The renal excretion of inositol in normal and diabetic human beings, J Clin Invest 33 (1954), 326-332.
24. Baillargeon JP, Luorno MJ, Apridonidze T, Nestler JE, Uncoupling between insulin and release of a D-chiro-inositolcontaining inositolphosphoglycan mediator of insulin action in obesewomenwith polycystic ovary syndrome, Metab Syndr Relat Disord 8 (2010), 127-136.